Dr. Kim has received research support from Takeda Pharmaceuticals North America and Pfizer, and tuition support for the Pharmacoepidemiology Program at the Harvard School of Public Health, funded by Pfizer and Asisa. Dr. Solomon has received research support from Abbott Immunology, Amgen, and Lilly and from the Consortium of Rheumatology Researchers of North America, and serves in unpaid roles on two Pfizer sponsored trials.
Changes in Use of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States During 1983–2009
Version of Record online: 26 AUG 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 9, pages 1529–1533, September 2013
How to Cite
Kim, S. C., Yelin, E., Tonner, C. and Solomon, D. H. (2013), Changes in Use of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis in the United States During 1983–2009. Arthritis Care Res, 65: 1529–1533. doi: 10.1002/acr.21997
- Issue online: 26 AUG 2013
- Version of Record online: 26 AUG 2013
- Accepted manuscript online: 5 MAR 2013 03:30PM EST
- Manuscript Accepted: 21 FEB 2013
- Manuscript Received: 27 NOV 2012
- NIH. Grant Numbers: K23-AR-059677, P60-AR-053308-06, K24-AR-055989, P60-AR-047782, R21-DE-018750, R01-AR-056215
- 12012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.Arthritis Care Res (Hoboken)2012;64:625–39., , , , , , et al.
- 8Prevalence and predictors of disability in valued life activities among individuals with rheumatoid arthritis.Ann Rheum Dis2006;69:1803–8., , .